מזומני החברה: inovio.com (INO)

Inovio Pharmaceuticals (INO) relies on stable demand for antivirals, yet faces risks due to potential disruptions in Asian supplies. The change in cash balance demonstrates the business's liquidity, with the indicator currently standing at 0.05. The company is implementing energy-efficient technologies in its laboratories, preparing for the 2026 launch of its first commercial DNA drug on the US market.
פילוחים אנליטיים של חברת Inovio Pharmaceuticals

Institutional capital assesses the attractiveness of Inovio Pharmaceuticals (INO) through the lens of financial autonomy and the capacity to fund R&D. This indicator measures the volume of liquid assets, allowing operational cash levels to serve as a gauge of the business's independence from debt capital. For a DNA vaccine developer, such reserves are critical when diversifying the pipeline to minimize regulatory risks. A sufficient cash cushion confirms the asset's resilience during periods of clinical trials.